Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
having resistance at .05 because starting 7/01/11 the high was .05 and started to form a long term cup...did not reach that high until now...consolidation and lower volume while forming a handle...a 2 1/2 year pattern is strong....we should break out of the handle on large volume....
I would like to see it at least trade....I guess it will move around Feb. one way or another
CHART...here is my long term chart stats I also posted on yahoo...
revisited the chart....the start of the cup pattern July 2011... the high was 1.80 and then dropped from there..1.80 is our resistance we need to start closing over
so we ended the cup formation on 1/14/2014 with a high of 1.83 and a close of 1.779 and have been forming a sideways handle since...what a beautiful 2 1/2 year cup...picture perfect...and very strong...patience pays off
every time NITE or ARCA takes over the bid and ask on Chromadex it moves down....especially with ARCA...is the same thing happening here?
I own for quite a while chromadex...nice profits so far but not done...everything they have been working on with the launch of their key ingredients that they are taking to market are just now starting to come to fruition....good things to come
no he didn't
no he didn't
today is a buying opp...we are forming a nice doji on the chart today...usually signals reversal...back up
re: ID Supermoney...I don't think he is just a short...seems more like a nut that believes in spreading the wealth around...take from the earner and give to the one sitting on their butt...
I know what u are saying but we have come up a long way on no news...up from .76 on 10/08 to high of 1.78....we had a year long uptrend until then...now we are climbing fast...I guess it depends when u bought the stock and at what price and how many shs u have...I am very happy.....there's more to come....cdxc is just getting started now
I'm not disappointed..just the opposite....Friday high 1.69 close 1.61....today high 1.78 close 1.70...we closed above yesterday's high....chart looks great..and I am not going anywhere...patience is golden with this stock...it it starting to pay off...
OPKO Health's Rayaldy And Fall Prevention In The Elderly
I am long OPKO Health Inc. (OPK) because of Rayaldy Capsules, OPKO's new vitamin D drug. I am not a stock analyst; my qualifications are listed on my Seeking Alpha profile. For the last eleven years, I have been reading, writing, and speaking about vitamin D as the the director and founder of the public interest, non-profit Vitamin D Council. My peer-reviewed publications in scientific journals are listed here.
In an earlier article, I speculated on possible additional indications for Rayaldy above and beyond the initial indication for which Rayaldy is currently being developed - secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. SHPT is characterized by chronic elevation of blood parathyroid hormone (PTH) levels, and it develops in these patients primarily as a consequence of vitamin D insufficiency. These Rayaldy trials are important as elevated PTH is associated with significant increased cardiovascular mortality in these patients. However, in this article, I will concentrate on just one potential additional indication for Rayaldy: the prevention of falls in the elderly.
Rayaldy is a first-in-class modified-release product that treats SHPT by correcting the underlying vitamin D insufficiency, a condition characterized by low blood levels of a prohormone known as 25-hydroxyvitamin D (25D). Rayaldy steadily boosts the blood 25D levels in a physiological manner due to its unique modified-release formulation.
Rayaldy will directly compete with nutritional vitamin D (vitamin D3 or vitamin D2), which requires comparatively high doses to increase blood 25D. Vitamin D2 is available over-the-counter (OTC) or by prescription, and vitamin D3 is available OTC only. For unclear reasons, nutritional vitamin D has been found to be ineffective in treating SHPT in CKD patients.
Rayaldy will also compete with prescription vitamin D hormone therapies, such as Hectorol Capsules (Sanofi (SNY)), paricalcitol capsules or calcitriol capsules. These therapies effectively lower PTH when administered in sufficiently high doses, but fail to correct the underlying vitamin D insufficiency. They often cause hypercalcemia (too much calcium in the blood), which can accelerate CKD progression via calcification of the kidneys, a risk that causes most physicians to prescribe these therapies with caution (usually at sub-therapeutic doses). Physicians understand that vitamin D hormone therapies are not effective or indicated for correcting vitamin D insufficiency.
In discussing Rayaldy's possible role in preventing falls, one needs to know Rayaldy's relationship to nutritional vitamin D. Rayaldy is a modified-release formulation containing the form of 25D that is normally made in the body from vitamin D3, namely 25-hydroxyvitamin D3 (25D3). OPKO's Phase 2 trials have shown that Rayaldy effectively increases blood 25D3 levels and effectively lowers blood PTH; the Phase 2 effect size was substantial.
The administered 25D3 is subsequently metabolized into calcitriol, which is a steroid hormone similar to cortisol or testosterone. The body can only make adequate calcitriol when blood 25D3 levels are sufficiently high (at least 30-40 ng/mL). All of vitamin D's health benefits are thought to depend on sufficiently high 25D3 levels.
Falls among the elderly are costly, both financially and medically. In 2010, falls among older adults cost the U.S. health care system $30 billion. By 2020, the annual direct and indirect cost of fall injuries is expected to reach $54.9 billion. Of people over age 65, one in three fall every year. In 2011, emergency departments treated 2.4 million nonfatal fall injuries among older adults; more than 689,000 of these patients had to be hospitalized.
Doctors are at a loss as how to prevent falls. There is no drug approved by the U.S. Food and Drug Administration (FDA) to prevent falls. Multiple prescription medications are often cited as the cause of falls, but doctors find it difficult to reduce the dose of these medications lest the treated disease or symptoms return. Regular exercise helps prevent falls, as does vision correction, but the effect size is modest. It helps to try to "fall proof" a home, but such efforts are usually problematic. Modern medicine would quickly embrace any prescription medication that helped to prevent falls.
To the best of my knowledge, all studies of daily OTC vitamin D3 in significant doses point to effective prevention of falls in the elderly. For example, a 2001 German study of elderly women found vitamin D3 caused a 46% reduction in falls. A 2003 Swiss study of elderly women found 800 IU/day of vitamin D3 plus calcium reduced the risk of falling by 49% compared with calcium alone. A 2009 German study of the elderly found 800 IU vitamin D3 reduced falls by 27% and reduced body sway by 28%. In fact, at least 10 university-based randomized controlled clinical trials have shown daily vitamin D3 prevents falls, and higher daily doses (> 800 IU/day) work when lower doses do not.
A meta-analysis is a study that combines the results of multiple independent clinical trials. Four rigorous meta-analyses (2004, 2009, 2010 and 2011) all concluded that vitamin D3 prevents falls. The U.S. Preventive Services Task Force recommends vitamin D to reduce falls in the elderly. The Centers for Disease Control and Prevention make the same recommendation. The American Geriatrics Society states, "vitamin D supplements of at least 800 IU per day should be considered for people... who are otherwise at increased risk for falls."
Vitamin D's effect size in preventing falls is substantial, with the four meta-analyses showing a 13%, 14%, 20% and 24% decreased risk of falling with vitamin D3. However, those meta-analyses included studies using only 400 IU/day, an almost meaningless dose. When studies using at least 800 IU/day are combined, the effect size was no less than 24%.
The mechanism by which vitamin D3 prevents falls is fairly well understood. It increases blood levels of 25D3 and thereby corrects vitamin D insufficiency, which increases muscle strength and restores balance in the elderly. Higher 25D3 levels are associated with better balance in the elderly. Surprisingly, blood 25D3 levels of 50 ng/mL were associated with better balance in the elderly than levels of 30 ng/ml, a level widely thought to be adequate. The same study showed vitamin D3 reduced body sway in the elderly by 28%. It also improved choice reaction time in the elderly, a crucial capability to prevent falls.
More recently, a study from Tufts University showed 4,000 IU/day of vitamin D3 increased muscle fiber diameter in mobility-limited elderly vitamin D deficient women. So, vitamin D improves muscle strength, balance, body sway, reaction time and muscle fiber size in vitamin D deficient elderly, thus preventing falls.
By the way, in 2009, my colleagues and I found convincing evidence that these same mechanisms are operative in improving athletic performance in vitamin D deficient athletes. We concluded that the reason the Russians and East Germans dominated world sports between 1955 and 1985 was because trainers from these two countries routinely irradiated their elite athletes with vitamin D-producing ultraviolet light during those 30 years.
Rayaldy may or may not be more effective than OTC vitamin D3 in preventing falls in the elderly. The active ingredient in Rayaldy is 25D3, the substrate that the body needs for fall prevention. Studies indicating that nutritional vitamin D3 has health benefits, such as prevention of falls in the elderly, clearly imply that Rayaldy will have the same or better benefit, since Rayaldy is at least five times more potent in boosting blood 25D3 levels than is OTC vitamin D3.
As evidence of the unsatisfactoriness of OTC vitamin D3 to prevent falls, consider the fact that vitamin D3's efficacy in preventing falls has been recognized for at least a decade and that nutritional vitamin D3 has been available for decades. Despite widespread recommendations, how many of the elderly currently take vitamin D3 to prevent falls? How many doctors routinely recommend OTC vitamin D3 to prevent falls? No one knows for sure, but ask some older people that you know and I suspect you will find that few take daily vitamin D3 to prevent falls despite a strong rationale and widespread recommendations by respected organizations that they do so.
Besides OTC vitamin D3, Rayaldy will compete with vitamin D2 which is available OTC in low doses or in 50,000 IU capsules with a prescription. Vitamin D2 is not human vitamin D and does not normally have a role in human physiology since dietary sources (other than supplements) are rare. Studies have shown vitamin D2 is inferior to vitamin D3 in raising blood 25D levels. Prescription vitamin D2 is administered in supraphysiological intermittent doses, not physiological daily doses. One study showed that high intermittent doses actually increase the risk of falls, and I am unable to find any convincing studies showing that administration of prescription vitamin D2 significantly reduce falls.
There remains some risk with Rayaldy. Enthusiasm over vitamins in the past, such as vitamin E and C, has waned when negative data emerged from appropriately designed clinical trials. Current Phase 3 trials of Rayaldy in CKD may fail. While four meta-analyses have all shown vitamin D3 reduces falls, phase 2 or 3 studies with Rayaldy may not bear this out. Furthermore, Rayaldy and vitamin D3 are not identical compounds; it is possible that vitamin D3 may have some presently unknown and unique benefits. Also, OPKO may elect not to develop Rayaldy for the indication of preventing falls in the elderly. Finally, competitors (currently there are none) may beat OPKO to the new falls indication.
My educated guess is that Rayaldy will eventually be approved by the FDA to prevent falls in the elderly. While I think OTC vitamin D3 in adequate doses will prevent falls as well as Rayaldy, it may be decades before such comparison studies are done. However, if OTC vitamin D3 would be an effective market competitor, it would already be widely used to prevent falls, as it has been available for decades. An effective prescription drug to prevent falls, like Rayaldy, would be rapidly embraced by the medical profession.
A good example is the prescription sleeping pill Rozerem, a melatonin receptor agonist. It has been known for years that OTC melatonin improves sleep. However, that did not prevent a melatonin mimic from being approved by the FDA. Rozeram did not have to beat melatonin in FDA trials, only beat placebo. There are many other similar examples. The same will be true of Rayaldy and OTC vitamin D3.
The FDA clinical trials necessary to approve Rayaldy to prevent falls will only include elderly patients with vitamin D insufficiency who have fallen twice or more during the most recent six months (frequent fallers). This will make the effect size greater than 24% and thus more likely to be found statistically significant in phase 2 and phase 3 trials. In addition, Rayaldy will not be under dosed; it is being administered in doses of 1 or 2 capsules per day in the currently ongoing Phase 3 trials; each 30 microgram capsule is approximately equivalent to 5,000 IU of vitamin D3.
Finally, the potential good that a prescription for Rayaldy could do in preventing falls in the elderly is immense. Everyone over the age of 65 is at an increased risk for falls. According to Wikipedia, the number of senior citizens in the U.S. was about 35 million in 2010. By 2020, more than 50 million Americans will be 65 years of age or older.
being profitable...keep in mind that this is just one deal only in network marketing sales channel in the United States, Canada and Philippines...Frost has rights outside the U.S. ....their words....be the first....not anywhere near the only...
"The health and wellness stories behind NIAGEN(TM) and PURENERGY(TM) make each ingredient ideal candidates for us to launch a suite of wellness products that will accelerate the growth in our new wellness segment," says Craig Jerabeck, CEO of 5LINX(R) . "We view this deal as an incredible opportunity for 5LINX(R) to be among the first to offer dietary supplements featuring NIAGEN(TM) Nicotinamide Riboside and PURENERGY(TM)."
ID Supermoney.....you act like Frost shouldn't make $$$ off of his hard work in his own company...I guess you are all for that liberal way of thinking...redistribution of wealth...u think maybe Frost should just hand over his $$$ to all of us????
no one is making you buy or sell any shares of OPK....I am not selling my shares to him or anyone else..I'm holding them...and when OPK is profitable as all get out and then he sells the company like he has done before I take the ride with him and make a boat load of money....so what is your point???? my point is to make money in the stock market...I could care less what you trade or Frost or anyone else....so your statement is ridiculous.....
he's not...he has said it a number of times....he can not think of a better company out there to invest his money in then OPK...once he gets 51% of the company...he can do whatever he wants....look for him to sell after that and the next things on the pipeline to come to fruition....he is getting up there...he won't quit until he is dead but he will sell....
are they getting ready for M&A...sure sounds like it....
ChromaDex® Appoints Former Nestle Executive to Its Board of Directors
announced today an addition to its board of directors with the appointment of Steve Allen as an independent director.
Allen, age 64, has extensive experience in negotiating merger and acquisition deals and coordinating related due diligence. He has many years of experience handling both in and out-licensing agreements with technology providers and branded companies.
Allen retired from Nestle in December 2009 after a 30-year career in sales, marketing and general management. In 2002, he joined the Mergers and Acquisitions group of Nestle. He was heavily involved in their venture capital investments (Nestle has over $800 million invested in a variety of venture funds) as well as out licensing technologies.
He is currently non-executive Vice-Chairman of 6 Pacific Group (http://www.6pacificgroup.com), a Los Angeles based boutique advisory and investment firm, which assists food and beverage companies with capital formation, acquisitions and divestitures. Recently the firm represented New Chapter in the sale to Procter & Gamble -- one of the most significant acquisitions in the supplement business in recent years.
Allen co-founded and is a member of the Screening Committee of Nutrition Capital Network (http://www.nutritioncapital.com), a business that brings together entrepreneurs and investors in the nutrition and food industries. The major global food and beverage companies (e.g. Coca-Cola, Unilever, General Mills, PepsiCo, Campbell's, Amway, Hershey's and Nestle) are cornerstone investors in Nutrition Capital Network and attend the three meetings each year where exciting new investment and partnering opportunities are presented.
Allen is also the Managing Partner of California Agricultural Orchards LLC, which owns almond properties in the Central Valley of California and is President of the Board of the North American Foundation for the University of Leeds (http://www.leeds.ac.uk) where he obtained a B.Sc. with Honors.
Commenting on the appointment, Allen stated, "I have known of and followed ChromaDex for years, and am proud to join its Board of Directors. The Company and its management have an excellent reputation within the nutritional supplement industry and the accomplishments in their ingredient technologies business, in such a short time frame, is nothing short of outstanding. I feel my experience, skill sets and industry contacts are very well suited for this appointment. I look forward working with Frank Jaksch and entire ChromaDex team."
Frank Jaksch, Jr., CEO and co-founder of ChromaDex, commented, "It is with great pride and enthusiasm that I welcome Steve as a ChromaDex director. His tremendous insight and experience in the nutritional industry will be a great asset to both our Board and management team."
I said there was something up with tmguns....he is full of crap...
the month before ended @ 1.70 and that month opened at 1.71 even though it went up that was the start of the downtrend...but in watching the chart now....it looks like we could be starting to form a handle right here around 1.60....time will tell...
because we have broken all the other lower resistance... the main resistance going back to 7/30/10 you have resistance in the 1.67 - 1.71 range...and the chart also shows a long term cup that starting forming in july 2011.....high was also 1.71...so if we start to form a handle it should be around that pps....JMHO
chart looks great....1.71 looks to be the resistance...closing above that takes us to 2....
just chill...not for long...short bozo picked the wrong stock but mostly the wrong man to screw with....
LOL...we are not following the sheep...we are following the bulls...cover your short...that would be the smart thing for you
@tmguns...quit pulling at straws.....at what price are u short
your name says it all....
I am sure cdxc knows that and even if they get a piece of that multi-billion $$$$ market it bodes really well for cdxc....Canada has already reduced the limit of caffeine allowed in these drinks and some states here also...it is coming from the govt soon...I'll bet on that....
Monster Beverage Lawsuit Against San Francisco Thrown Out
Monster Beverage Corp. (MNST)’s lawsuit challenging San Francisco City Attorney Dennis Herrera’s attempt to regulate the caffeine content of its products and change its marketing was thrown out of federal court.
U.S. District Judge Virginia Phillips in Riverside, California, dismissed the case because Herrera has a suit against Monster that involves important state interests, and U.S. Food and Drug Administration regulation of Monster’s products don’t clearly preempt the actions, according to her order.
Herrera said the dismissal clears the way for his lawsuit, pending in state court in San Francisco, to proceed. He claims Monster’s marketing targets children while its products have known risks to health and safety.
“Monster Energy’s federal suit was a meritless ploy to stop our state consumer-protection case, and I’m grateful to the court for issuing an unequivocal dismissal,” Herrera said.
Monster denies marketing to children. It says the ingredients in its drinks are safe and its products are clearly labeled. The Corona, California-based company claims Herrera is violating its right to free speech and his claims are preempted by FDA regulations.
Mike Sitrick, a spokesman for Monster, didn’t immediately respond to an e-mail message seeking comment on the ruling.
The FDA said last year it is investigating whether energy drinks may cause harm when consumed in excess or by young people or those in with heart conditions. The agency may move to regulate the drinks’ use or labeling.
http://www.bloomberg.com/news/2013-12-16/monster-beverage-lawsuit-against-san-francisco-thrown-out-1-.html
I don't care what you guys say...tmguns is not on the same side as longs....I have seen this many times ...so have you
I agree...I was thinking tmguns has an alternative objective also...I ask how long he has owned the stock...how invested is he in it...and why he is trying to discredit Frost with his selective words....I have owned opk for quite some time....I have been up and down...I don't care...I am in this stock for the payoff in the end.....and Frost has bought for years now...sometimes every day sometimes not....seems like tmguns is trying to find silly negative things like this to post about....
tmguns...u act like this is the only stock ever attacked by a short scum like bozza...it happens all the time...he is desperate...hence the 45 page report...look at his holdings...he loses money for his investors a lot....every time he attacks he covers his shorts...with opk ...he never counted on it going up as fast as it has...now he is desperate for his clients...he is scum ...he will do anything...even lie....you can bet on the fact he covers it every time he does this...
Opko Health (OPK): TheStreetSweeper stands bullish following Q&A with Dr. Phillip Frost
http://thestreetsweeper.org/
Frost has been here before...short scum mean nothing to him....
@tmguns...then sell the stock and be done...I'm holding long
I agree with him...that is why I bought chromadex in the first place....lots of potential....
CLOSE: 1.02......BUYS 182,000 SELLS 29,786....looks like .96 support is holding .....
Friday: 274,214 VOLUME BUYS = 247,479 SELLS = 26,735 and the buys look good today....just low volume...
.96 is strong support......
u had better be quick with your short then lol